BNTX:NASDAQ
BioNTech SE - ADR
၉၅.၈၄ US$
arrow_downward
-၁.၁၆%(-၁.၁၂) 1D
၉၅.၈၄ US$
၀.၀၀% (၀.၀၀)
bedtimeAfter hours
Closed: အောက် ၁၂, GMT-၄ ၁၆:၀၀:၀၂ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
၉၇.၆၁ US$
High
၉၈.၆၀ US$
Low
၉၅.၇၅ US$
Mkt. cap
ဋေ ၂.၄၁ ထ
Avg. vol.
၉.၈၆ သိန်း
Volume
၁.၂၆ သန်း
52-wk high
၁၂၄.၀၀ US$
52-wk low
၇၉.၅၂ US$
EPS
-၇.၅၂ US$
Beta
၁.၂၂
Shares outstanding
၂၅.၁၂ ကုဋေ
No. of employees
၈ ထောင်
Open
၉၇.၆၁ US$
High
၉၈.၆၀ US$
Low
၉၅.၇၅ US$
Mkt. cap
ဋေ ၂.၄၁ ထ
Avg. vol.
၉.၈၆ သိန်း
Volume
၁.၂၆ သန်း
52-wk high
၁၂၄.၀၀ US$
52-wk low
၇၉.၅၂ US$
EPS
-၇.၅၂ US$
Beta
၁.၂၂
Shares outstanding
၂၅.၁၂ ကုဋေ
No. of employees
၈ ထောင်
News stories
From web sources and news partners
Zacks
·
ပြီးခဲ့သည့် ၆ နာရီ
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
Yahoo Finance
·
ပြီးခဲ့သည့် ၂ ရက်
Why Did BioNTech (BNTX) Move Today?
Yahoo Finance
·
ပြီးခဲ့သည့် ၃ ရက်
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR